Management Change/Compensation Form 8 K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers

Resignation and Appointment of Directors

On September 30, 2024, George Sekulich resigned as a member of the Board of Directors, or the Board, of Emmaus Life Sciences, Inc. ("we," "us," "our," "Emmaus" or the "company") in connection with the termination of his employment as our Chief Commercial Officer on October 4, 2024.

At a meeting of the Board held on October 1, 2024, the Board appointed Jon Kuwahara to fill the resulting vacancy on the Board of Directors. The Board also appointed Mr. Kuwahara to serve as the Chair of the two-person Audit Committee of the Board.

Mr. Kuwahara, age 58, previously served as a director of Emmaus and as Chairman of the Audit Committee and a member of the Corporate Governance and Compensation Committees of the Board from January 2016 to September 2018. He has served as Vice President - Finance of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), San Diego, California, since August 2021. Prior to that time, Mr. Kuwahara served as Senior Vice President - Finance and Administration of Novus Therapeutics, Inc. (NASDAQ: NVUS), Irvine, California, from July 2016 to July 2021 and in senior finance and accounting positions with a number of other life sciences companies. Mr. Kuwahara is a Certified Public Accountant and holds a Bachelor of Business Administration, Accounting, degree from the University of Hawaii at Manoa, Honolulu, Hawaii.

There are no family relationships between Mr. Kuwahara and any of our other directors, executive officers, or persons nominated or chosen to become a director or executive officer. Mr. Kuwahara is not party to any current or proposed transaction for which disclosure is required under Item 404(a) of Regulation S-K.